<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tarek Alhamad, MD, MS, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Malone, MB, BCh, FASN, FRCPI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1742288603"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney allograft rejection is a major cause of allograft dysfunction. Some kidneys do not regain function even with maximal antirejection therapy.</p><p>There has been a dramatic reduction in the incidence of acute rejection due to the introduction of potent immunosuppressive drugs in the past three decades. However, optimizing immunosuppression to both prevent allograft rejection and minimize drug toxicity, posttransplant diabetes mellitus, dyslipidemia, infection, and malignancy remains challenging.</p><p>This topic will review the clinical features and diagnosis of acute kidney allograft rejection. The treatment of acute rejection and the general evaluation of kidney allograft dysfunction are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p></p><p class="headingAnchor" id="H4157780745"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The following terminology will be used throughout this topic review:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection</strong> – Acute kidney allograft rejection is defined as an acute deterioration in allograft function associated with specific pathologic changes in the allograft. There are two principal forms of acute rejection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute T cell–mediated (cellular) rejection (TCMR) </strong>– This is characterized by lymphocytic infiltration of the tubules, interstitium, and, in some cases, the arterial intima. Acute TCMR is caused by T cells that react to foreign antigens, the most common of which are donor histocompatibility antigens, present within tubules, interstitium, vessels, and glomeruli of the allograft. However, natural killer cells, macrophages, and other cells may also contribute. (See <a class="local">'Acute T cell-mediated (cellular) rejection'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Active antibody-mediated rejection (ABMR) </strong>– The diagnosis of ABMR is established by morphologic evidence of acute tissue injury, evidence of circulating donor-specific antibodies (DSAs), and evidence of antibody-endothelial cell interaction (such as C4d deposition in the allograft). However, the diagnosis of ABMR can be made without DSAs or C4d.</p><p></p><p class="bulletIndent2">ABMR is thought to be caused by the binding of circulating antibodies to donor alloantigens on graft endothelial cells, which results in inflammation, cell damage, and, ultimately, graft dysfunction. Such antigens most commonly include human leukocyte antigen (HLA) class I and class II antigens and, in recipients of ABO-incompatible transplants, ABO blood group antigens; other non-major histocompatibility complex (MHC) alloantigens on the endothelium may also be targeted [<a href="#rid1">1-4</a>]. (See <a class="local">'Active antibody-mediated rejection'</a> below.)</p><p></p><p class="bulletIndent1">Acute TCMR and ABMR may coexist at the same time in the allograft (ie, mixed acute rejection). Acute rejection may also coexist with chronic rejection. (See <a class="local">'Mixed acute rejection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic rejection </strong>– Chronic rejection is characterized by a slow deterioration in allograft function associated with variable degrees of proteinuria and hypertension and is an important contributor to late graft loss. It usually occurs after the first year of transplantation and can occur with or without active inflammation. The three currently recognized types are chronic active ABMR, chronic inactive ABMR, and chronic active TCMR [<a href="#rid5">5,6</a>]. (See <a class="local">'Chronic rejection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical rejection</strong> – Subclinical rejection is defined as the presence of histologic evidence of acute rejection on biopsy without an elevation in the serum creatinine concentration [<a href="#rid7">7-16</a>]. Subclinical rejection is detected by a surveillance, or protocol, biopsy, which is obtained at a protocol-driven, prespecified time after transplantation or on detection of de novo DSAs [<a href="#rid17">17</a>] rather than for an indication such as allograft dysfunction. Most of the reports of subclinical rejection involve TCMR [<a href="#rid7">7-14</a>]. However, there are reports of allografts with histologic manifestations of ABMR in the absence of functional deterioration of kidney function [<a href="#rid17">17,18</a>]. (See <a class="local">'Subclinical rejection'</a> below.)</p><p></p><p class="headingAnchor" id="H604321110"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3224391873"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The incidence of acute rejection within the first posttransplant year has decreased dramatically over the past three decades with the advent of more potent immunosuppressive drugs. For kidney transplants performed in 2020, the rate of acute rejection in the first posttransplant year was 9.3 percent for recipients aged 18 to 34 years, 7.6 percent for recipients aged 35 to 49 years, 6.1 percent for recipients aged 50 to 64 years, and 5.3 percent for recipients aged ≥65 years  (<a class="graphic graphic_figure graphicRef142615" href="/d/graphic/142615.html" rel="external">figure 1</a>) [<a href="#rid19">19</a>]. By comparison, 50 to 60 percent of kidney transplant recipients in the 1980s experienced at least one acute rejection episode [<a href="#rid20">20</a>].</p><p>Overall, the rate of acute rejection in the first year posttransplant is 1 to 2 percent lower for living-donor compared with deceased-donor kidney transplant recipients. This difference is probably related to better matching in living-donor transplants and less cold ischemia time.</p><p>Data on the incidence of acute T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) come primarily from studies from centers that perform surveillance/protocol biopsies, and, as such, they may differ from the national estimates of acute rejection cited above.</p><p class="bulletIndent1"><span class="glyph">●</span>In one systematic review that included 12 studies of patients on <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, the incidence of acute TCMR (greater than Banff borderline) was 16 percent during the first posttransplant year [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another systematic review of 28 cohort studies, the incidence of active ABMR ranged from 1.1 to 21.5 percent although most studies reported an incidence of 3 to 12 percent within the first posttransplant year [<a href="#rid22">22</a>]. The incidence of chronic ABMR ranged from 7.5 to 20.1 percent at up to 10 years of follow-up.</p><p></p><p class="headingAnchor" id="H4130566020"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Patients with one or more of the following risk factors are considered to be at high immunologic risk for acute rejection [<a href="#rid23">23</a>] (see  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Assessment of immunologic risk'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>One or more human leukocyte antigen (HLA) mismatches</p><p class="bulletIndent1"><span class="glyph">●</span>Younger recipient and older donor age</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a donor-specific antibody (DSA)</p><p class="bulletIndent1"><span class="glyph">●</span>Blood group incompatibility</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed onset of graft function</p><p class="bulletIndent1"><span class="glyph">●</span>Cold ischemia time greater than 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Previous episode of rejection</p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of a second or greater transplant</p><p class="bulletIndent1"><span class="glyph">●</span>Medication nonadherence</p><p></p><p>Historically, an elevated pretransplant calculated panel reactive antibody (cPRA) was considered a risk factor for acute rejection and graft loss [<a href="#rid23">23</a>]. This was based on studies that used older and less sensitive and specific technology for PRA testing. With newer technology for PRA testing using single antigen bead assays and virtual cross-matching, elevated cPRA (a measure of probable anti-HLA antibody formation) in the absence of DSA is not associated with inferior graft survival or ABMR in the modern era [<a href="#rid24">24-26</a>]. (See  <a class="medical medical_review" href="/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'Determination of patient sensitization'</a>.)</p><p class="headingAnchor" id="H1825314920"><span class="h2">Clinical impact</span><span class="headingEndMark"> — </span>Acute rejection episodes are generally associated with a reduction in long-term allograft survival although not all rejection episodes have the same impact on long-term graft function. Factors such as timing of rejection, severity and number of acute rejections, and degree of recovery of function after treatment all affect the long-term outcome [<a href="#rid27">27</a>]. If kidney function returns to baseline, acute rejection does not necessarily cause irreparable damage or impact long-term graft survival [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure"</a>.)</p><p>Despite significant reductions in the incidence of acute rejection over the last decade, there has not been a similar improvement in long-term allograft survival. The underlying reasons for this are unclear. Possibilities include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients that are at high risk for TCMR are also at high risk for ABMR. Although the use of potent induction agents may prevent acute TCMR in predisposed recipients, these patients may develop early interstitial fibrosis/tubular atrophy (IF/TA) that is antibody mediated and not easy to diagnose or treat [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The beneficial effects of lower incidence of acute rejection are offset by the negative effects of calcineurin inhibitor nephrotoxicity and overimmunosuppression [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More potent induction therapy might prevent acute rejections that would have responded well to therapy. This leaves ABMR and mixed TCMR and ABMR that frequently do not respond as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A substantial proportion (39 percent) of biopsy-proven TCMR persists even after treatment with anti-rejection therapy [<a href="#rid21">21</a>]. However, most of these rejections were treated with pulsed glucocorticoids only.</p><p></p><p class="headingAnchor" id="H2966916863"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H327418703"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Most episodes of acute rejection occur within the first six months after transplantation, with many occurring early after surgery. Rejection after 12 months is typically from nonadherence to or overaggressive reduction in immunosuppression.</p><p>Most patients with acute allograft rejection are asymptomatic. However, patients rarely present with fever, malaise, and graft pain and/or tenderness [<a href="#rid32">32</a>]. These manifestations are uncommon with modern immunosuppressive drug regimens, particularly those including calcineurin inhibitors, unless immunosuppression is completely discontinued. Since most patients are asymptomatic, acute rejection is usually suggested by abnormal laboratory testing. (See <a class="local">'Laboratory findings'</a> below.)</p><p class="headingAnchor" id="H3632568176"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings that can be observed in patients with kidney allograft rejection include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated serum creatinine</strong> – An acute rise in the serum creatinine is the most common laboratory finding among patients with acute allograft rejection. A rising serum creatinine level, however, is not specific for acute rejection. It is a relatively late development in the course of a rejection episode and usually indicates the presence of significant histologic damage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>New or worsening proteinuria</strong> – New or increasing proteinuria greater than 1 g/day can be seen in the setting of active antibody-mediated rejection (ABMR) or chronic ABMR. However, proteinuria after transplantation may also be caused by glomerulosclerosis or tubulointerstitial fibrosis from chronic rejection, recurrent glomerular disease, chronic allograft nephropathy, and de novo glomerulopathies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pyuria</strong> – Pyuria may be present in patients with acute rejection but can also be seen in the setting of urinary tract infection. (See  <a class="medical medical_review" href="/d/html/7298.html" rel="external">"Urinary tract infection in kidney transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated plasma donor-derived cell-free DNA level</strong> – Donor-derived cell-free DNA (dd-cfDNA) is released into the bloodstream by dead cells in the injured allograft. Fractional plasma levels of dd-cfDNA &gt;1 percent or serially increasing levels are associated with episodes of acute rejection [<a href="#rid33">33-41</a>]. In one study in which plasma levels of dd-cfDNA were measured in 102 kidney transplant recipients with acute elevations in serum creatinine, a plasma dd-cfDNA level of &gt;1 percent had a positive predictive value (PPV) and negative predictive value (NPV) for acute rejection (T cell-mediated rejection [TCMR] or ABMR) of 61 and 84 percent, respectively [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Other studies have suggested lower cutoff levels such as &gt;0.75 or &gt;0.5 percent, with one study showing that a 0.5 percent cutoff was better at detecting borderline rejection and early TCMR [<a href="#rid38">38,41</a>]. In general, dd-cfDNA is a continuous number. The higher the percentage, the higher the PPV for rejection, and the lower the percentage, the higher the NPV for the absence of rejection. Levels of dd-cfDNA cannot be used to distinguish between TCMR and ABMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>De novo donor-specific antibody (DSA) or rising DSA levels</strong> – The development of de novo serum antibodies directed against the donor's HLA antigens (ie, DSA) or rising DSA titers in a patient with a preexisting DSA can occur in patients with acute rejection and has been associated with ABMR [<a href="#rid42">42-44</a>]. In a systematic review and meta-analysis of seven retrospective cohort studies (1119 patients), the presence of DSA detected by solid-phase assay, despite a negative flow cytometry crossmatch result, was associated with nearly double the risk for ABMR (relative risk [RR] 1.98, 95% CI 1.36-2.89) and a higher risk of graft failure (RR 1.76, 95% CI 1.13-2.74) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">DSAs to non-HLA antigens have also been described in patients with ABMR. Such non-HLA antigens include the angiotensin II receptor [<a href="#rid1">1</a>], MHC class I polypeptide-related sequence A (<em>MICA</em>) [<a href="#rid45">45,46</a>], and endothelial cell antigens [<a href="#rid45">45</a>]. Other antigens have been identified in the research setting but are not currently tested in the routine clinical setting [<a href="#rid3">3,47</a>].</p><p></p><p class="bulletIndent1">A negative DSA does not rule out the diagnosis of ABMR. In one study of 280 kidney biopsies from 272 kidney transplant recipients, for example, DSA was negative in 56 percent cases of ABMR diagnosed through molecular phenotyping and 51 percent of cases of ABMR diagnosed through histologic assessment of the biopsy [<a href="#rid48">48</a>]. (See <a class="local">'Active antibody-mediated rejection'</a> below.)</p><p></p><p class="bulletIndent1">Not all DSAs are equally pathogenic. In one study, complement-binding antibodies (ie, C1q-binding DSAs) were associated with an increased rate of ABMR and worse graft survival compared with non-complement-binding DSAs [<a href="#rid49">49</a>]. However, testing DSAs for C1q-binding is not widely performed, and it is likely that there are non-complement-binding DSAs that are clinically relevant and not detected by this assay. These issues are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'C1q binding assay'</a> and  <a class="medical medical_review" href="/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure", section on 'Sensitization'</a>.)</p><p></p><p class="bulletIndent1">A discussion of the assays used to detect DSAs is presented separately. (See  <a class="medical medical_review" href="/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'Crossmatch testing for donor-specific antibodies'</a>.)</p><p></p><p class="headingAnchor" id="H3965136766"><span class="h2">Imaging findings</span><span class="headingEndMark"> — </span>Imaging studies are neither sensitive nor specific for acute rejection and are generally not used for the diagnosis of rejection. However, they may be obtained to rule out other causes of acute allograft dysfunction. Ultrasonography may show increased graft size, with loss of the corticomedullary junction, prominent hypoechoic pyramids, and decreased echogenicity of the renal sinus [<a href="#rid32">32</a>]. Duplex Doppler ultrasonography may show elevated resistive indices, but this finding may also be observed with ureteral obstruction, acute tubular necrosis, renal vein occlusion, pyelonephritis, and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> toxicity [<a href="#rid50">50,51</a>]. Nuclear medicine renal scans may show delayed visualization of kidneys.</p><p class="headingAnchor" id="H3311429785"><span class="h1">MONITORING OF ASYMPTOMATIC PATIENTS</span><span class="headingEndMark"> — </span>Since many kidney transplant recipients with acute rejection are asymptomatic, the primary means of monitoring for rejection is laboratory testing. The frequency of laboratory monitoring depends upon the time since transplantation and may vary among transplant centers. (See  <a class="medical medical_review" href="/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine laboratory monitoring </strong>– The following lab tests are obtained at every lab visit to monitor allograft function (see <a class="local">'Laboratory findings'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis with, if available, a sediment examination</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spot urine protein-to-creatinine ratio (some experts obtain a urine dipstick first and measure a spot urine protein-to-creatinine ratio if the dipstick reveals more than trace albuminuria) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor specific antibody (DSA)</strong> – There is no consensus on when to test for DSA in the absence of allograft dysfunction. The frequency of DSA monitoring varies among transplant centers and depends upon the patient's immunologic risk. Some transplant centers perform routine DSA testing annually in stable transplant recipients.</p><p></p><p class="bulletIndent1">Posttransplant monitoring for the development of DSAs may permit the early detection of antibody-mediated rejection (ABMR) and allograft dysfunction, particularly in high-risk patients. In a single-center, prospective study of 49 transplant recipients, the majority of patients with ABMR developed DSAs before or concurrent with the ABMR event [<a href="#rid52">52</a>]. By comparison, only 3 of 41 without ABMR developed DSAs.</p><p></p><p class="bulletIndent1">The presence of circulating DSAs alone does not indicate active rejection; however, it does identify a patient at higher risk for ABMR. Other clinical and laboratory parameters need to be assessed in parallel with DSA testing. In the setting of an increasing or new DSA but no other indicators of acute rejection or a normal kidney allograft biopsy, most transplant centers would only augment maintenance immunosuppression. (See  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor-derived cell-free DNA (dd-cfDNA) </strong>– Some centers routinely monitor high-risk patients with dd-cfDNA levels at specified time points (eg, at 1, 3, 6, 9, and 12 months), with the rationale that monitoring would allow for early diagnosis of acute rejection. However, practice varies considerably, and some centers do not routinely monitor dd-cfDNA levels, while others may monitor dd-cfDNA levels only in patients at high risk for rejection, patients at higher risk of biopsy-related complications, or patients who have been treated for acute rejection. Routine monitoring of dd-cfDNA has been shown to detect an elevated dd-cfDNA three to four months before the onset of clinically evident rejection [<a href="#rid53">53</a>]. However, there are no data showing that routine monitoring results in improved kidney survival. At many transplant centers, monitoring of dd-cfDNA has replaced protocol biopsies. </p><p></p><p class="bulletIndent1">Two studies have demonstrated the benefits of monitoring dd-cfDNA in kidney transplant recipients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one multicenter study of 1092 adult kidney transplant recipients who were monitored with dd-cfDNA as part of their standard of care, elevations in dd-cfDNA (≥0.5 percent) were associated with significant eGFR decline at three years posttransplant, and persistently elevated dd-cfDNA (more than one result ≥0.5 percent) nearly doubled the risk of a 25 percent decline in eGFR [<a href="#rid53">53</a>]. An elevated dd-cfDNA was also associated with a nearly threefold elevation in the risk of future de novo DSA over two years of follow-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another multicenter study that included 280 kidney transplant biopsies, approximately half of all cases of ABMR were DSA negative; however, dd-cfDNA was elevated in patients with DSA-negative and DSA-positive ABMR [<a href="#rid48">48</a>]. A dd-cfDNA ≥1 percent predicted ABMR better than DSA positivity (area under the curve [AUC] 0.85 versus 0.66, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral blood gene expression profiling </strong>– Blood gene expression testing is another biomarker that has been used at some centers for surveillance monitoring of kidney allograft health [<a href="#rid54">54,55</a>]. The test was developed as a microarray-based assay that analyzes gene expression profiles (GEP) in the peripheral blood. The results of the test are expressed as Transplant eXcellence (TX; stable serum creatinine, normal biopsy results) versus not-TX. TX refers to a high likelihood of immune quiescence and a low likelihood of histologic rejection; not-TX refers to a higher risk of immune activation and higher likelihood of rejection.</p><p></p><p class="bulletIndent1">In an observational study of 208 transplant recipients with 428 surveillance biopsies, a non-TX result on GEP assay had a positive predictive value (PPV) of 47 percent and negative predictive value (NPV) of 82 percent for the diagnosis of subclinical rejection [<a href="#rid56">56</a>]. By comparison, a positive dd-cfDNA (defined as &gt;0.7 percent) had a PPV of 56 percent and NPV of 84 percent. Combining a positive dd-cfDNA and a non-TX result on GEP assay increased the PPV to 81 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance/protocol biopsies</strong> – A small proportion (approximately 17 percent) of transplant centers perform surveillance (or protocol) kidney biopsies at specified time points after transplantation [<a href="#rid57">57</a>]. Surveillance/protocol biopsies are usually performed to identify subclinical rejection, which is characterized by histologic changes of acute rejection in the absence of an increased serum creatinine concentration. There are no data on the utility of surveillance/protocol biopsies in the modern era with the availability of less invasive biomarkers such as dd-cfDNA and gene expression panels. Biopsies are costly, inconvenient, associated with complications and sampling error, and rarely have agreement among interpretation, even among expert pathologists. However, protocol biopsies may have a limited role in carefully designed clinical trials. (See <a class="local">'Subclinical rejection'</a> below.)</p><p></p><p class="headingAnchor" id="H3772026866"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H414675786"><span class="h2">When to suspect rejection</span><span class="headingEndMark"> — </span>Acute rejection should be suspected in patients with one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>New increase in serum creatinine of ≥25 percent from baseline <strong>or</strong> a serum creatinine that is higher than expected (such as in recently transplanted patients whose serum creatinine stops decreasing earlier than expected after transplantation). However, in patients who are at increased risk for antibody-mediated rejection (ABMR) (eg, highly sensitized patients, recipients of ABO-incompatible kidney allografts, patients with donor-specific antibodies [DSAs], and patients with inadequate immunosuppression), any incremental increase in serum creatinine should raise the suspicion for the possibility of acute rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New or increasing proteinuria &gt;1 g/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worsening hypertension. (See  <a class="medical medical_review" href="/d/html/7360.html" rel="external">"Hypertension after kidney transplantation", section on 'Allograft dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma donor-derived cell-free DNA (dd-cfDNA) &gt;1 percent or a rising trend in serial dd-cfDNA measurements. (See <a class="local">'Laboratory findings'</a> above and <a class="local">'Monitoring of asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A non-TX result on a peripheral blood gene expression profile (GEP) assay combined with a dd-cfDNA &gt;1 percent. (See <a class="local">'Monitoring of asymptomatic patients'</a> above.)</p><p></p><p>All kidney transplant recipients who are suspected of acute rejection should undergo an evaluation to exclude other potential causes of acute allograft dysfunction. The evaluation of acute kidney allograft dysfunction is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Evaluation of acute allograft dysfunction'</a>.)</p><p class="headingAnchor" id="H102006630"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of acute rejection is presently defined histologically by kidney allograft biopsy. There are no specific laboratory findings that can accurately diagnose acute rejection. A kidney allograft biopsy is required to differentiate between T cell-mediated rejection (TCMR) and ABMR, to accurately grade the severity of rejection, and to determine the degree of irreversible kidney damage (interstitial fibrosis/tubular atrophy [IF/TA]). Biopsy of the kidney allograft can also reveal other causes of kidney inflammation and injury, including cytomegalovirus (CMV) disease, BK polyomavirus-associated nephropathy (BKPyVAN), interstitial nephritis, pyelonephritis, de novo or recurrent glomerular disease, and posttransplant lymphoproliferative disease (PTLD). (See <a class="local">'Differential diagnosis'</a> below.)</p><p>A classification system for TCMR and ABMR has been developed and revised by an expert panel of pathologists, immunologists, physicians, surgeons, and immunogeneticists to standardize the histologic criteria for diagnosing and grading the severity of rejection (ie, Banff classification) [<a href="#rid5">5,58-65</a>].</p><p>It may be difficult to distinguish between active ABMR and severe acute TCMR, and the two processes may also coexist. In reality, the diagnoses of ABMR and TCMR are part of a continuum representing different presentations of the alloimmune response. In up to 25 percent of cases of allograft dysfunction attributed, at least in part, to ABMR, the histologic findings are suggestive of only TCMR or acute tubular injury [<a href="#rid66">66</a>]. It is important to identify ABMR, if possible, since ABMR is more refractory to treatment and, unless adequately treated, often results in kidney allograft loss [<a href="#rid67">67</a>].</p><p>Other methods used to help diagnosis acute kidney allograft rejection have been the focus of a large number of investigators and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7325.html" rel="external">"Investigational methods in the diagnosis of acute kidney allograft rejection"</a>.)</p><p class="headingAnchor" id="H3415333693"><span class="h3">Acute T cell-mediated (cellular) rejection</span><span class="headingEndMark"> — </span>The diagnosis of acute TCMR is established histologically by the presence of certain pathologic features in the kidney allograft biopsy, which include  (<a class="graphic graphic_picture graphicRef116699" href="/d/graphic/116699.html" rel="external">picture 1</a>) [<a href="#rid58">58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial infiltration with mononuclear cells, most of which are lymphocytes. Monocytes, plasma cells, and occasionally eosinophils may also be present. Neutrophils are uncommon and suggest the diagnosis of infection or ABMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubular inflammation (ie, tubulitis), whereby infiltrating lymphocytes and monocytes cross the tubular basement membranes and extend into the walls and lumina of the tubules. Tubulitis must be documented in normal-appearing, nonatrophic tubules. The presence of patchy mononuclear cell infiltrates without tubulitis is not uncommon in normal functioning kidney allografts and is not, by itself, sufficient to make the diagnosis of acute TCMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vascular inflammation, whereby lymphocytes, monocytes, and foam cells infiltrate the arterial endothelium but rarely extend into the muscularis (ie, intimal arteritis). Intimal arteritis can also be seen in ABMR. </p><p></p><p>The severity of acute TCMR is graded using the Banff classification, which assesses these three specific features (interstitial inflammation [i], tubulitis [t], and intimal arteritis [v]) and scores them on a scale from one to three [<a href="#rid65">65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline – Foci of tubulitis (t1, t2, or t3) with mild interstitial inflammation (i1), or mild (t1) tubulitis with moderate to severe interstitial inflammation (i2 or i3).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IA – Significant interstitial inflammation (&gt;25 percent of nonsclerotic cortical parenchyma; i2 or i3) and foci of moderate tubulitis (t2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IB – Significant interstitial inflammation (&gt;25 percent of nonsclerotic cortical parenchyma; i2 or i3) and foci of severe tubulitis (t3).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IIA – Mild to moderate intimal arteritis (v1) with or without interstitial inflammation and tubulitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IIB – Severe intimal arteritis comprising &gt;25 percent of the luminal area (v2) with or without interstitial inflammation and tubulitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>III – Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation (v3).</p><p></p><p>The diagnosis of acute TCMR requires a histologic score of at least t2 <strong>and</strong> i2; a v lesion is not required for the diagnosis of TCMR. Any scores below this (eg, i1+t2 or i2+t1) are considered to be borderline. The significance of the presence of intimal arteritis alone (eg, v1) is controversial but still allows for the diagnosis of TCMR.</p><p>The treatment of acute TCMR is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>.)</p><p class="headingAnchor" id="H1778369631"><span class="h3">Active antibody-mediated rejection</span><span class="headingEndMark"> — </span>The diagnosis of active ABMR is established by the presence of the following three criteria  (<a class="graphic graphic_table graphicRef103469" href="/d/graphic/103469.html" rel="external">table 1</a>) [<a href="#rid65">65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic evidence of acute tissue injury</strong> – The kidney allograft biopsy should demonstrate histologic evidence of acute tissue injury. The findings in ABMR can vary widely from acute tubular injury, microvascular inflammation (ie, infiltration of glomerular and peritubular capillarities by lymphocytes and other immune cells that may include neutrophils; also known as capillaritis) to intimal or transmural arteritis, or acute thrombotic microangiopathy  (<a class="graphic graphic_picture graphicRef81994" href="/d/graphic/81994.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef70194" href="/d/graphic/70194.html" rel="external">picture 3</a>). Other less common lesions can include endothelialitis, fibrinoid necrosis, or transmural inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence of current/recent antibody interaction with vascular endothelium </strong>–<strong> </strong>This is defined by the presence of at least one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Linear immunofluorescence or immunohistochemical staining for C4d (a degradation product of the classic complement pathway) in the peritubular capillaries (PTCs). C4d binds covalently to the endothelial and collagen basement membranes, thereby serving as an immunologic footprint of complement activation and antibody-mediated injury. In normal kidneys, C4d is detectable in the glomerular mesangium and at the vascular pole. Deposition of C4d in the PTCs has only been described in kidney allografts and represents complement activity directed against donor antigen  (<a class="graphic graphic_picture graphicRef68422" href="/d/graphic/68422.html" rel="external">picture 4</a>) [<a href="#rid68">68</a>]. In one study, C4d staining in the PTCs was 95 percent sensitive and 96 percent specific for the diagnosis of ABMR [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased expression of gene transcripts/classifiers in the biopsy tissue that are strongly associated with ABMR. (See  <a class="medical medical_review" href="/d/html/7325.html" rel="external">"Investigational methods in the diagnosis of acute kidney allograft rejection", section on 'The molecular microscope'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least moderate microvascular inflammation in the kidney allograft biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serologic evidence of circulating DSAs</strong> – The presence of serum antibodies directed against the donor's human leukocyte antigen (HLA) class I and II antigens (ie, DSAs) supports a diagnosis of ABMR (see <a class="local">'Laboratory findings'</a> above). If DSA testing is negative, the presence of C4d staining in the PTCs and/or the expression of validated gene panels strongly associated with ABMR can substitute for DSAs in the diagnosis of ABMR [<a href="#rid5">5</a>].</p><p></p><p>If all three of these criteria are met, the patient is diagnosed with ABMR. However, certain clinical scenarios exist in which patients have ABMR but do not meet all three criteria:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with</strong> <strong>C4d-negative ABMR </strong>– Some patients have histologic evidence of ABMR (microcirculatory inflammation) and a positive DSA but have little or no C4d staining in the PTCs, an entity recognized as C4d-negative ABMR [<a href="#rid69">69,70</a>]. In C4d-negative ABMR, DSA binding to endothelial cells may cause injury through complement-independent mechanisms. In one study of 2006 adults who underwent kidney transplantation between 2004 and 2014, 10.3 percent developed ABMR; approximately one-quarter of these cases were C4d-negative [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Patients with C4d-negative ABMR are treated using the same approach as that for patients with C4d-positive ABMR. (See  <a class="medical medical_review" href="/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection", section on 'Patients with C4d-negative ABMR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without a detectable DSA </strong>– As discussed above, DSA testing may be negative among patients with ABMR (see <a class="local">'Laboratory findings'</a> above). Patients who have ABMR without a detectable circulating DSA may not benefit from antibody-lowering therapies used to treat ABMR (such as plasmapheresis).</p><p></p><p class="bulletIndent1">Some patients with negative testing for anti-HLA antibodies may have antibodies against non-HLA antigens. If anti-HLA antibody testing is negative but the patient has evidence of acute tissue injury and antibody interaction with the vascular endothelium, testing for non-HLA antibodies can be considered. However, there are no universally established or validated clinical assays to detect these antibodies. Thus, testing for non-HLA antibodies is of limited utility. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1">Cases in which C4d staining is positive but DSA cannot be detected may also result from DSA being below the level of detection due to immunoadsorption by the graft. Detection of HLA antibodies in eluates from allograft biopsy samples may help overcome this challenge [<a href="#rid72">72</a>] but is not part of current clinical practice.</p><p></p><p class="bulletIndent1">The prevention and treatment of ABMR are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p></p><p class="headingAnchor" id="H2570073330"><span class="h3">Mixed acute rejection</span><span class="headingEndMark"> — </span>The diagnosis of mixed acute rejection is established when both acute TCMR and ABMR coexist within the same kidney allograft. Criteria for the diagnosis of TCMR and ABMR are discussed above. (See <a class="local">'Acute T cell-mediated (cellular) rejection'</a> above and <a class="local">'Active antibody-mediated rejection'</a> above.)</p><p>Patients with mixed acute rejection may be misdiagnosed as having only TCMR or ABMR, which can lead to these patients being undertreated or incorrectly treated. </p><p>The treatment of mixed acute rejection is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection", section on 'Patients with mixed acute rejection'</a>.)</p><p class="headingAnchor" id="H92981207"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>As described above, most patients with acute rejection are asymptomatic and present only with an elevated creatinine [<a href="#rid32">32</a>]. In patients who present with fever, malaise, oliguria, and/or graft pain or tenderness, the diagnosis of infection, urinary leak, and obstruction should also be considered. (See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"</a>.)</p><p>Among kidney transplant recipients, the causes of an elevated serum creatinine concentration vary with the time after transplantation and are generally classified as immediate-, early-, and late-period kidney allograft dysfunction. The evaluation and differential diagnosis of kidney allograft dysfunction are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p>Other diseases, such as posttransplant lymphoproliferative disease (PTLD), cytomegalovirus (CMV) disease, BK polyomavirus-associated nephropathy (BKPyVAN), interstitial nephritis, and pyelonephritis, may have similar histologic findings to allograft rejection:</p><p class="bulletIndent1"><span class="glyph">●</span>CMV infection – CMV may manifest as an increased serum creatinine, with a kidney biopsy histologic appearance similar to that of rejection. CMV infection can be distinguished by the presence of cytoplasmic or nuclear viral inclusions and CMV-specific immunohistochemical staining on kidney biopsy. In one study, treatment of the CMV rather than antirejection treatment was associated with "reversal" of rejection and improvement in graft function in 17 of 21 patients [<a href="#rid73">73</a>]. In general, whole blood or plasma CMV viral load testing will identify patients with active CMV disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BKPyVAN – The histologic appearance of BKPyVAN may mimic the tubulitis and/or arteritis classically associated with rejection [<a href="#rid74">74</a>]. Among such patients, it is extremely important to attempt to differentiate BKPyVAN from rejection, as the two treatments are diametrically opposed and increased immunosuppression in the setting of BKPyVAN will lead to further viral proliferation and potential allograft loss. However, distinguishing BKPyVAN from acute rejection on the basis of histology is not always possible, and, in some patients, the two diagnoses may simultaneously overlap.</p><p></p><p class="bulletIndent1">Among all patients, special stains for BKPyV should be performed on the biopsy sample if there is concern for BKPyVAN, even in the absence of typical viral inclusions on the biopsy. It is essential that medullary tissue be available for analysis since BKPyV is tropic for medullary tubules more than cortical tubules. (See  <a class="medical medical_review" href="/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug- or infection-related interstitial nephritis – Drug- or infection-related interstitial nephritis may also mimic rejection. Peripheral eosinophilia may suggest drug-induced acute interstitial nephritis, although its absence does not exclude the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplant pyelonephritis – Transplant pyelonephritis can cause an elevation in serum creatinine as well as interstitial and tubular infiltrates. However, the infiltrate mostly consists of polymorphonuclear cells rather than lymphocytes. Urine culture will usually be positive for gram-negative organisms, although gram-positive bacteria can cause urinary tract infections in rare cases. (See  <a class="medical medical_review" href="/d/html/7298.html" rel="external">"Urinary tract infection in kidney transplant recipients", section on 'Microbiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PTLD – PTLD is suggested by a diffuse lymphocytic infiltrate of such severity that it is difficult to visualize tubular architecture, which can occasionally be observed in patients with severe T cell-mediated rejection (TCMR) (frequently secondary to nonadherence with immunosuppression).</p><p></p><p class="bulletIndent1">Since the treatment options for rejection and PTLD are markedly different, additional studies must be performed to differentiate the two possibilities. Studies include special stains for T and B cell populations, Epstein-Barr virus (EBV) antigens, and monoclonal light chains, as well as quantitative EBV polymerase chain reaction and serum and urine protein electrophoresis. Imaging of the graft should also include the abdomen, pelvis, and any other clinically relevant areas (see  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>). Detection of specific cell markers for T cells, B cells, plasma cells, and monocytes may also be useful to guide rejection therapy in the setting of a significant cellular infiltrate with graft dysfunction.</p><p></p><p class="headingAnchor" id="H559909325"><span class="h1">SUBCLINICAL REJECTION</span><span class="headingEndMark"> — </span>Subclinical rejection is when histologic changes of acute rejection are observed in the absence of an increased serum creatinine concentration [<a href="#rid7">7-14</a>]. Subclinical rejection is usually detected by surveillance (or protocol) biopsies. (See <a class="local">'Monitoring of asymptomatic patients'</a> above.)</p><p>The incidence of subclinical rejection in the first six months after a kidney transplantation is highly variable and depends on several factors, including degree of human leukocyte antigen (HLA) matching, presence of donor-specific antibodies (DSAs), immunosuppressive protocol, and the incidence of delayed graft function [<a href="#rid11">11</a>].</p><p>Many [<a href="#rid7">7,8,10,75-80</a>], though not all [<a href="#rid9">9,12</a>], studies have demonstrated an association between subclinical rejection demonstrated by protocol biopsy and decreased allograft survival and/or function. Patients with subclinical antibody-mediated rejection (ABMR) appear to exhibit worse graft function compared with those who have subclinical T cell-mediated rejection (TCMR). In one study, graft survival at eight years in patients with subclinical ABMR (defined as stable kidney function with histologic features of capillaritis and/or glomerulitis and evidence of DSA) detected on protocol biopsy at one year posttransplant was 56 percent, compared with 88 percent in those with subclinical TCMR [<a href="#rid15">15</a>]. Patients with treated subclinical TCMR had similar graft survival as those without rejection (90 percent at eight years).</p><p>It is unclear if the administration of therapy to patients with subclinical rejection improves clinical outcomes. This is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection", section on 'Borderline and subclinical rejection'</a>.)</p><p class="headingAnchor" id="H3037450254"><span class="h1">CHRONIC REJECTION</span><span class="headingEndMark"> — </span>Chronic rejection refers to rejection that usually occurs after the first posttransplant year, in the absence of calcineurin inhibitor nephrotoxicity and other causes of allograft dysfunction. It can occur without histologic evidence of inflammation. Chronic kidney allograft rejection is classified as chronic active T cell-mediated rejection (TCMR), chronic active antibody-mediated rejection (ABMR), and chronic inactive ABMR.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic active TCMR </strong>– Chronic active TCMR is characterized by the presence of the inflammatory infiltrates in areas of interstitial fibrosis and tubular atrophy (IF/TA) in the kidney allograft [<a href="#rid5">5,65</a>]. Like acute TCMR, the severity of chronic TCMR is also graded using the Banff classification [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic ABMR</strong> – Chronic ABMR refers to chronic microvascular injury that leads to remodeling of the glomerular or peritubular capillaries. Chronic ABMR is further classified into chronic active and chronic inactive subtypes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic active ABMR</strong> – Chronic active ABMR generally develops late (&gt;6 months posttransplant) and can occur in patients with or without a history of active ABMR [<a href="#rid81">81</a>]. The only difference between the diagnostic criteria for chronic active and active ABMR is the requirement for histologic evidence of chronic tissue injury, which is defined by certain histologic lesions such as transplant glomerulopathy (double contouring of glomerular capillary walls  (<a class="graphic graphic_picture graphicRef58239" href="/d/graphic/58239.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef79914" href="/d/graphic/79914.html" rel="external">picture 6</a>)), severe multilayering of the peritubular capillary basement membrane, and/or arterial intimal fibrosis; otherwise, the remaining two criteria are the same [<a href="#rid65">65</a>]. (See <a class="local">'Active antibody-mediated rejection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic inactive ABMR</strong> – Chronic inactive ABMR is characterized by histologic evidence of chronic tissue injury (ie, transplant glomerulopathy and/or peritubular capillary basement membrane multilayering), without microvascular inflammation and without evidence of current/recent antibody interaction with the endothelium (eg, no C4d deposition in peritubular capillaries) [<a href="#rid65">65</a>]. Patients with chronic inactive ABMR have a prior documented diagnosis of active or chronic active ABMR and/or documented prior evidence of donor-specific antibody (DSA).</p><p></p><p class="bulletIndent1">The treatment of chronic ABMR is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection", section on 'Treatment of chronic antibody-mediated rejection'</a>.)</p><p></p><p class="headingAnchor" id="H1754084663"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>– Acute kidney allograft rejection is defined as an acute deterioration in allograft function associated with specific pathologic changes in the allograft. There are two principal forms, acute T cell-mediated (cellular) rejection (TCMR) and active antibody-mediated rejection (ABMR). ABMR and acute TCMR may coexist at the same time in the allograft. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical presentation </strong>– Most episodes of acute rejection occur within the first six months after transplantation, with many occurring early after surgery. Patients are mostly asymptomatic but occasionally present with fever, malaise, oliguria, and graft pain and/or tenderness. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory findings </strong>– An acute rise in the serum creatinine is the most common laboratory finding in acute rejection. New or worsening proteinuria or pyuria may also be present. Fractional plasma levels of donor-derived cell-free DNA (dd-cfDNA) &gt;1 percent or serially increasing levels are associated with acute rejection. The development of de novo serum antibodies against donor HLA antigens (ie, donor-specific antibody [DSA]) or rising DSA titers in a patient with a preexisting DSA can also occur in patients with acute rejection. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging findings </strong>– Most findings obtained by kidney imaging are nonspecific, and such studies are generally performed to exclude other causes of acute kidney injury. (See <a class="local">'Imaging findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring of asymptomatic patients </strong>– Since many kidney transplant recipients with acute rejection are asymptomatic, the primary means of monitoring for rejection is laboratory testing. The frequency of laboratory monitoring depends upon the time since transplantation and may vary among transplant centers. (See <a class="local">'Monitoring of asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to suspect rejection </strong>– Acute rejection should be suspected in patients with one or more of the following (see <a class="local">'When to suspect rejection'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>New increase in serum creatinine of ≥25 percent from baseline <strong>or</strong> a serum creatinine that is higher than expected. However, in patients who are at increased risk for ABMR, any incremental increase in serum creatinine should raise the suspicion for the possibility of acute rejection.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>New or increasing proteinuria &gt;1 g/day.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Worsening hypertension. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Plasma dd-cfDNA &gt;1 percent or a rising trend in serial dd-cfDNA measurements. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Establishing the diagnosis </strong>– The diagnosis of acute rejection is presently established by kidney allograft biopsy. A kidney allograft biopsy is required to differentiate between TCMR and ABMR, accurately grade the severity of rejection, and determine the degree of irreversible kidney damage (interstitial fibrosis/tubular atrophy [IF/TA]). Biopsy of the kidney allograft can also reveal other causes of kidney inflammation and injury, including cytomegalovirus (CMV) disease, BK polyomavirus-associated nephropathy (BKPyVAN), interstitial nephritis, pyelonephritis, de novo or recurrent glomerular disease, and posttransplant lymphoproliferative disease. (See <a class="local">'Establishing the diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic rejection </strong>– Chronic rejection is characterized by a slow deterioration in allograft function and is an important contributor to late graft loss. It usually occurs after the first year of transplantation and can occur with or without active inflammation. The three classic types are chronic active ABMR, chronic inactive ABMR, and chronic active TCMR. (See <a class="local">'Chronic rejection'</a> above.)</p><p></p><p class="headingAnchor" id="H1524203984"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge W James Chon, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558.</a></li><li><a class="nounderline abstract_t">Tiriveedhi V, Angaswamy N, Brand D, et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol 2012; 167:158.</a></li><li><a class="nounderline abstract_t">Rose ML. Role of anti-vimentin antibodies in allograft rejection. Hum Immunol 2013; 74:1459.</a></li><li><a class="nounderline abstract_t">Cardinal H, Dieudé M, Brassard N, et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant 2013; 13:861.</a></li><li><a class="nounderline abstract_t">Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 2018; 18:293.</a></li><li><a class="nounderline abstract_t">Hara S. Current pathological perspectives on chronic rejection in renal allografts. Clin Exp Nephrol 2017; 21:943.</a></li><li><a class="nounderline abstract_t">Rush DN, Henry SF, Jeffery JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57:208.</a></li><li><a class="nounderline abstract_t">Shapiro R, Jordan ML, Scantlebury VP, et al. Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist? Transplantation 2000; 69:440.</a></li><li><a class="nounderline abstract_t">Roberts IS, Reddy S, Russell C, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004; 77:1194.</a></li><li><a class="nounderline abstract_t">Kee TY, Chapman JR, O'Connell PJ, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006; 82:36.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6:2006.</a></li><li><a class="nounderline abstract_t">Scholten EM, Rowshani AT, Cremers S, et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17:2622.</a></li><li><a class="nounderline abstract_t">Serón D, Moreso F. Protocol biopsies in renal transplantation: prognostic value of structural monitoring. Kidney Int 2007; 72:690.</a></li><li><a class="nounderline abstract_t">Thaunat O, Legendre C, Morelon E, et al. To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation 2007; 84:671.</a></li><li><a class="nounderline abstract_t">Loupy A, Vernerey D, Tinel C, et al. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol 2015; 26:1721.</a></li><li><a class="nounderline abstract_t">Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9:2561.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Watarai Y, Takeda A, et al. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury. Transplantation 2016; 100:2194.</a></li><li><a class="nounderline abstract_t">Mengel M, Bogers J, Bosmans JL, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005; 5:1050.</a></li><li><a class="nounderline abstract_t">Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR 2021 Annual Data Report: Kidney. Am J Transplant 2023; 23:S21.</a></li><li class="breakAll">Cecka, JM, Terasaki, PI. Early rejection episodes. In: Clinical Transplants, Terasaki, PI (Eds), UCLA Tissue Typing Laboratory, Los Angeles 1989. p.425.</li><li><a class="nounderline abstract_t">Ho J, Okoli GN, Rabbani R, et al. Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis. Am J Transplant 2022; 22:772.</a></li><li><a class="nounderline abstract_t">Hart A, Singh D, Brown SJ, et al. Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review. Clin Transplant 2021; 35:e14320.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Wehmeier C, Hönger G, Cun H, et al. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients. Am J Transplant 2017; 17:2092.</a></li><li><a class="nounderline abstract_t">Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6:2307.</a></li><li><a class="nounderline abstract_t">Lan JH, Kadatz M, Chang DT, et al. Pretransplant Calculated Panel Reactive Antibody in the Absence of Donor-Specific Antibody and Kidney Allograft Survival. Clin J Am Soc Nephrol 2021; 16:275.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B, Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85:661.</a></li><li><a class="nounderline abstract_t">Madden RL, Mulhern JG, Benedetto BJ, et al. Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transpl Int 2000; 13:344.</a></li><li><a class="nounderline abstract_t">Vereerstraeten P, Abramowicz D, de Pauw L, Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63:1739.</a></li><li><a class="nounderline abstract_t">Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90:68.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378.</a></li><li class="breakAll">Pham, PTT, Nast, et al. Diagnosis and therapy of graft dysfunction. In: Chronic kidney disease, dialysis and transplantation, 2, Periera, BJG, Sayegh, MH, Blake, P (Eds), Elsevier Saunders, Philadelphia 2005. p.641.</li><li><a class="nounderline abstract_t">Bloom RD, Bromberg JS, Poggio ED, et al. Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol 2017; 28:2221.</a></li><li><a class="nounderline abstract_t">Lo YM, Tein MS, Pang CC, et al. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 1998; 351:1329.</a></li><li><a class="nounderline abstract_t">Snyder TM, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 2011; 108:6229.</a></li><li><a class="nounderline abstract_t">Hurkmans DP, Verhoeven JGHP, de Leur K, et al. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. J Immunother Cancer 2019; 7:182.</a></li><li><a class="nounderline abstract_t">Oellerich M, Shipkova M, Asendorf T, et al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant 2019; 19:3087.</a></li><li><a class="nounderline abstract_t">Huang E, Sethi S, Peng A, et al. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. Am J Transplant 2019; 19:1663.</a></li><li><a class="nounderline abstract_t">Sigdel TK, Archila FA, Constantin T, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med 2018; 8.</a></li><li><a class="nounderline abstract_t">Jordan SC, Bunnapradist S, Bromberg JS, et al. Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients. Transplant Direct 2018; 4:e379.</a></li><li><a class="nounderline abstract_t">Stites E, Kumar D, Olaitan O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. Am J Transplant 2020; 20:2491.</a></li><li><a class="nounderline abstract_t">Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7:1808.</a></li><li><a class="nounderline abstract_t">Zhang R. Donor-Specific Antibodies in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2018; 13:182.</a></li><li><a class="nounderline abstract_t">Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23:2061.</a></li><li><a class="nounderline abstract_t">Sun Q, Liu Z, Yin G, et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 2005; 79:1759.</a></li><li><a class="nounderline abstract_t">Carapito R, Aouadi I, Verniquet M, et al. The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. Nat Med 2022; 28:989.</a></li><li><a class="nounderline abstract_t">Angaswamy N, Klein C, Tiriveedhi V, et al. Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy. Am J Transplant 2014; 14:685.</a></li><li><a class="nounderline abstract_t">Halloran PF, Reeve J, Madill-Thomsen KS, et al. Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study. Transplantation 2023; 107:709.</a></li><li><a class="nounderline abstract_t">Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369:1215.</a></li><li><a class="nounderline abstract_t">Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15:219.</a></li><li><a class="nounderline abstract_t">Desvaux D, Schwarzinger M, Pastural M, et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation 2004; 78:647.</a></li><li><a class="nounderline abstract_t">Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79:591.</a></li><li><a class="nounderline abstract_t">Bu L, Gupta G, Pai A, et al. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int 2022; 101:793.</a></li><li><a class="nounderline abstract_t">Marsh CL, Kurian SM, Rice JC, et al. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function. Transplant Proc 2019; 51:722.</a></li><li><a class="nounderline abstract_t">Friedewald JJ, Kurian SM, Heilman RL, et al. Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant 2019; 19:98.</a></li><li><a class="nounderline abstract_t">Park S, Guo K, Heilman RL, et al. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2021; 16:1539.</a></li><li><a class="nounderline abstract_t">Mehta R, Cherikh W, Sood P, Hariharan S. Kidney allograft surveillance biopsy practices across US transplant centers: A UNOS survey. Clin Transplant 2017; 31.</a></li><li><a class="nounderline abstract_t">Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411.</a></li><li><a class="nounderline abstract_t">Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.</a></li><li><a class="nounderline abstract_t">Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12:563.</a></li><li><a class="nounderline abstract_t">Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753.</a></li><li><a class="nounderline abstract_t">Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708.</a></li><li><a class="nounderline abstract_t">Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518.</a></li><li><a class="nounderline abstract_t">Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272.</a></li><li><a class="nounderline abstract_t">Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 2020; 20:2318.</a></li><li><a class="nounderline abstract_t">Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779.</a></li><li><a class="nounderline abstract_t">Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381:313.</a></li><li><a class="nounderline abstract_t">Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464.</a></li><li><a class="nounderline abstract_t">Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011; 75:271.</a></li><li><a class="nounderline abstract_t">Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312.</a></li><li><a class="nounderline abstract_t">Orandi BJ, Alachkar N, Kraus ES, et al. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. Am J Transplant 2016; 16:213.</a></li><li><a class="nounderline abstract_t">Martin L, Guignier F, Bocrie O, et al. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy. Transplantation 2005; 79:1459.</a></li><li><a class="nounderline abstract_t">Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344:1737.</a></li><li><a class="nounderline abstract_t">McGilvray ID, Lajoie G, Humar A, Cattral MS. Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant 2003; 3:501.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Borrows RJ, Fung CL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78:242.</a></li><li><a class="nounderline abstract_t">Shishido S, Asanuma H, Nakai H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14:1046.</a></li><li><a class="nounderline abstract_t">Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5:2464.</a></li><li><a class="nounderline abstract_t">Choi BS, Shin MJ, Shin SJ, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5:1354.</a></li><li><a class="nounderline abstract_t">Moreso F, Ibernon M, Gomà M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6:747.</a></li><li><a class="nounderline abstract_t">Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7:356.</a></li><li><a class="nounderline abstract_t">Regele H, Böhmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13:2371.</a></li></ol></div><div id="topicVersionRevision">Topic 7352 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703421" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22132895" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23777935" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of anti-vimentin antibodies in allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432943" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29243394" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27848058" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Current pathological perspectives on chronic rejection in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8310509" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Histological findings in early routine biopsies of stable renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706058" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114084" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861939" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16796717" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The significance of subclinical rejection and the value of protocol biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899517" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597702" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Protocol biopsies in renal transplantation: prognostic value of structural monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17893596" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : To biopsy or not to biopsy? Should we screen the histology of stable renal grafts?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25556173" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19775320" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26636737" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816885" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37132350" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : OPTN/SRTR 2021 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37132350" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : OPTN/SRTR 2021 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34860468" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864724" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28245084" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transplanting the highly sensitized patient: The emory algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33495290" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pretransplant Calculated Panel Reactive Antibody in the Absence of Donor-Specific Antibody and Kidney Allograft Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337655" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of time of rejection on long-term graft survival in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052270" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9210497" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463643" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961990" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961990" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28280140" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cell-Free DNA and Active Rejection in Kidney Allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643800" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444804" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Universal noninvasive detection of solid organ transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300068" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062511" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30725531" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30583588" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30234148" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32056331" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524074" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28446536" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Donor-Specific Antibodies in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160511" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Donor-specific antibodies adversely affect kidney allograft outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15973182" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35288692" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24410875" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36190186" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24066742" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Complement-binding anti-HLA antibodies and kidney-allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694176" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Proteomic-based detection of urine proteins associated with acute renal allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371663" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753849" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34953773" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30979456" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985559" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34620649" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28251702" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Kidney allograft surveillance biopsy practices across US transplant centers: A UNOS survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8377384" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987096" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Banff 97 working classification of renal allograft pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22300494" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Banff 2011 Meeting report: new concepts in antibody-mediated rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294345" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Banff 07 classification of renal allograft pathology: updates and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780562" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17352710" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472190" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32463180" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856785" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182298" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Antibody-mediated vascular rejection of kidney allografts: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1747954" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21426880" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681822" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26317487" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15912120" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741857" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Late-acute renal allograft rejection and symptomless cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694076" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280685" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Natural history, risk factors, and impact of subclinical rejection in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660340" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162196" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Predicting subsequent decline in kidney allograft function from early surveillance biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888041" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16539631" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17283485" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Infiltrates in protocol biopsies from renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191982" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
